#USA #San Francisco #ImmunityBio #FDA Warning #Anktiva

ImmunityBio Faces Serious Legal Challenge

ImmunityBio, Inc. (NASDAQ: IBRX) is currently embroiled in a class action lawsuit that seeks to represent investors who acquired the company’s securities from January 19, 2026, to March 24, 2026. This legal action follows concerning news that the FDA has issued a warning to ImmunityBio regarding misleading claims related to its lead biologic product, Anktiva, as stated by the company's executive chairman and Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong.

On March 24, 2026, following the FDA's communication, ImmunityBio’s stock plummeted by over 21%, resulting in a staggering loss of nearly $2 billion in market capitalization. The FDA's warning indicated that statements made by Soon-Shiong during a direct-to-consumer podcast, where he claimed that Anktiva could treat a variety of cancers beyond its approved use, were considered misleading and unfounded.

The podcast, titled “Is the FDA BLOCKING Life Saving Cancer Treatments?” aired on January 19, 2026, where Soon-Shiong stated that, while Anktiva is officially approved for non-muscle invasive bladder cancer (NMIBC), it should be viewed as a treatment option for all forms of cancer. He also made various other claims that led to concerns from the FDA, which stated these claims were misleading and unsupported by substantial evidence.

The FDA subsequently took a formal stance, asserting that the promotional materials released by ImmunityBio gave a false impression of the drug’s efficacy, suggesting it could cure all cancer types. This is particularly alarming as the FDA underscored the potential public health risks stemming from such misleading claims. They highlighted that the materials lacked crucial information regarding Anktiva’s FDA-approved indication and how they misrepresented the treatment's long-term success rate for patients.

Reed Kathrein, a partner at Hagens Berman, the law firm leading the investigation, expressed the firm's commitment to thoroughly explore claims that ImmunityBio knowingly misled investors regarding the efficacy and indications of its product. They are particularly encouraging shareholders who have incurred substantial losses due to these developments to come forward and share their experiences.

This lawsuit isn't just a financial concern but brings to light ethical questions surrounding the marketing and promotion of medical products. Given that ImmunityBio is a biotechnology firm specialized in developing immunotherapies, the implications of this case could set precedential standards on how biotech companies communicate the efficacy of their treatments to the public and investors alike.

Hagens Berman is actively seeking evidence and testimonials from both investors who have been financially affected by these circumstances and any individuals who can provide insights related to the case. They are urging whistleblowers with non-public information to consider participating in this investigation and potentially benefit from the SEC Whistleblower program, which offers financial incentives for information leading to successful recoveries.

As of now, ImmunityBio's future remains uncertain, especially as regulatory scrutiny continues to intensify. The medical community and investors alike will be watching the developments of this case closely, as they may have broader implications not only for the company itself but also for the biotechnology industry as a whole.

In conclusion, ImmunityBio is at a critical juncture where the decisions made in light of this lawsuit may impact its operations and trustworthiness in the eyes of both investors and those seeking innovative cancer treatments. As this case progresses, it will be crucial for all parties involved to navigate the complexities of investor confidence and regulatory compliance responsibly. Stay tuned for updates on this evolving story.